Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2020/03/024377
CTRI/2020/03/024377
Not yet recruiting
Phase 2

A Single Arm Phase 2 Clinical Study To Evaluate The Efficacy Of Varunmoola Kwatha Orally And Nirgundi Taila Nasya In Kaphavrutta Vata With Special Reference To Hypothyroidism

DR Ashish Dattatray Kamble0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
DR Ashish Dattatray Kamble
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
DR Ashish Dattatray Kamble

Eligibility Criteria

Inclusion Criteria

  • •daignose case of hypothyroidism on basis if T3 T4 TSH levels
  • •patients TSH level above normal upto 30IU per ml
  • •patients having score more than or eual to 25 according to Billewicz scoring index for daignosis of hypothyroidism

Exclusion Criteria

  • •patients with age less than 18yrs and more than 60yrs
  • •patients having TSH more than 30 IU
  • •patients having hypertension daibetis mellitus hyperthyroidism
  • •lactating mothers
  • •patients with any infective diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Clinical study to evaluate BO-112 plus pembrolizumab in patients with advanced melanomaAdvanced melanoma after progression to immunotherapyMedDRA version: 20.0Level: LLTClassification code 10027155Term: Melanoma skinSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-003921-51-FRHighlight Therapeutics40
Recruiting
Phase 2
A clinical trial to evaluate the feasibility and efficacy of using Anastrozole before surgery for patients with hormone-related localized Breast Cancer with low proliferative capacityMalignant neoplasm of breastC04.557.470.200
RBR-5pygzhjHospital de Câncer de Barretos
Active, not recruiting
Phase 1
Study of the efficacy and safety of the Bintrafusp alfa (M7824) in previously treated cancer called malignant pleural mesothelioma.
EUCTR2020-004902-67-ESFundación GECP47
Active, not recruiting
Phase 1
A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer - OCTAVIAEpithelial ovarian cancer, fallopian tube or primary peritoneal carcinomaMedDRA version: 9.1 Level: LLT Classification code 10033128 Term: Ovarian cancerMedDRA version: 9.1 Level: LLT Classification code 10016180 Term: Fallopian tube cancerMedDRA version: 9.1 Level: LLT Classification code 10061344 Term: Peritoneal neoplasm
EUCTR2008-008336-85-GBF. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR189
Active, not recruiting
Not Applicable
A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer. - OCTAVIA
EUCTR2008-008336-85-SEF. Hoffmann-La Roche Ltd.,Pharmaceuticals Division, PDR180